Drugs / Autologous CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03121625 | Dec 2016 → Dec 2018 | leukemia, lymphoma | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03121625 ↗ |
| Action | Deplete | “preclinical studies have demonstrated effective killing of corresponding target cells” NCT03121625 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T cell immunotherapy (CAR-T)” NCT03121625 ↗ |